Advanced Oncology Nursing

Oncology Assessment

Performance Status Scales

ECOG Performance Status (0–4)

Grade	Description
0	Fully active, no restrictions
1	Restricted strenuous activity; ambulatory, light work capable
2	Ambulatory >50% of waking hours; self-care only, no work
3	Limited self-care; confined to bed/chair >50% of waking hours
4	Completely disabled; no self-care; fully confined to bed/chair

Karnofsky Performance Scale (0–100)

Score	Functional Status
100–80	Normal activity with no special care needed
70–50	Unable to work; lives at home with some assistance
40–20	Disabled; requires special care and assistance; hospitalization
10–0	Very sick; active supportive treatment; moribund

ℹECOG ≥3 or KPS ≤50 generally contraindicates aggressive chemotherapy. Document at every cycle.

TNM Staging System

T — Primary Tumour

TX: Tumour cannot be assessed
T0: No evidence of primary tumour
Tis: Carcinoma in situ
T1–T4: Increasing size and/or local extension

N — Regional Lymph Nodes

NX: Cannot be assessed
N0: No regional node metastasis
N1–N3: Increasing node involvement

M — Distant Metastasis

M0: No distant metastasis
M1: Distant metastasis present

Stage Grouping

Stage	Characteristics
I	Localised, small, no nodal spread
II	Larger local or limited nodal spread
III	Extensive local/regional spread
IV	Distant metastasis present (M1)

Cancer Pain Assessment — OPQRST

Letter	Question
O — Onset	When did it start? Sudden or gradual?
P — Provocation/Palliation	What makes it worse/better?
Q — Quality	Burning, stabbing, aching, gnawing?
R — Radiation	Does it spread? Where?
S — Severity	0–10 NRS or VAS scale
T — Timing	Constant, intermittent, breakthrough?

WHO Analgesic Ladder

Step 1 (mild pain 1–3): Non-opioid — paracetamol, NSAIDs ± adjuvants

Step 2 (moderate pain 4–6): Weak opioid — codeine, tramadol ± non-opioid ± adjuvants

Step 3 (severe pain 7–10): Strong opioid — morphine, oxycodone, fentanyl ± non-opioid ± adjuvants

Nutritional Status — PG-SGA

Patient-Generated Subjective Global Assessment is the gold standard for cancer nutrition screening.

Components

Weight history: Recent change in 1 month / 6 months
Food intake: Current vs usual — type and quantity
Symptoms: Nausea, vomiting, dysphagia, anorexia, pain, fatigue
Activities & Function: How activity has changed
Disease & metabolic demand: Cancer stage, comorbidities
Physical exam: Fat/muscle stores, fluid status

Scoring Thresholds

Score	Action
0–1	Routine reassessment
2–3	Patient & family education by dietitian/nurse
4–8	Dietitian referral, with pharmacist review as indicated
≥9	Critical need — intensive nutrition intervention

VTE Risk — Khorana Score

Validated tool to predict chemotherapy-associated VTE risk in ambulatory cancer patients.

Risk Factor	Points
High-risk cancer site (stomach, pancreas)	2
Very high-risk site (brain, kidney, bladder, uterus, lung, lymphoma, myeloma, testicular)	1
Pre-chemotherapy platelet count ≥350 × 10⁹/L	1
Haemoglobin <10 g/dL or use of ESA	1
Pre-chemotherapy WBC >11 × 10⁹/L	1
BMI ≥35 kg/m²	1

Score 0 — Low risk Score 1–2 — Intermediate risk Score ≥3 — High risk — consider prophylaxis

⚠High-risk patients (≥3): Discuss anticoagulation prophylaxis (LMWH or DOAC) with oncology team per local protocol.

Tumour Markers — Nursing Awareness

⚠Tumour markers are NOT diagnostic tools alone. Nurses monitor trends — they do not interpret results in isolation.

Marker	Associated Cancer	Clinical Use
PSA	Prostate	Screening, monitoring post-treatment
CEA	Colorectal, lung, breast	Monitoring, not screening
AFP	Hepatocellular, testicular	Staging, monitoring response
CA-125	Ovarian	Monitoring treatment response
CA 19-9	Pancreatic, biliary	Monitoring, prognosis indicator

Nursing Role

Ensure correct sampling (fasting status, collection tube type)
Document and trend values over treatment cycles
Alert physician of significant rises or unexpected changes

Oncological Emergencies — Recognition

Superior Vena Cava (SVC) Obstruction

Signs: Facial/neck swelling, distended neck veins, dyspnoea, headache worse when bending forward, plethora.

Causes: Lung cancer, lymphoma, mediastinal mass.

🚨Sit upright, O₂, IV access in LOWER limbs, urgent oncology/radiology referral. Do NOT delay.

Spinal Cord Compression (MSCC)

Signs: New or worsening back pain, limb weakness, sensory changes, bladder/bowel dysfunction — a RED FLAG combination.

Causes: Vertebral metastases (breast, prostate, lung, myeloma most common).

🚨Immobilise, urgent MRI within 24h, dexamethasone 16 mg IV stat, neurosurgery/radiotherapy consult.

Hypercalcaemia of Malignancy

Signs: "Bones, groans, stones, psychic moans" — bone pain, nausea/constipation, polyuria/renal stones, confusion/depression.

Corrected Ca >2.6 mmol/L — symptomatic above 3.0.

⚠IV 0.9% NaCl hydration, bisphosphonate (zoledronic acid), calcitonin for rapid effect, monitor ECG.

Tumour Lysis Syndrome (TLS)

Laboratory: Hyperuricaemia, hyperkalaemia, hyperphosphataemia, hypocalcaemia, AKI.

High-risk: Bulky lymphoma, AML, ALL, post-chemotherapy initiation.

🚨Aggressive IV hydration, allopurinol or rasburicase, strict I&O monitoring, cardiac monitoring, renal team involvement.

Chemotherapy Administration

Cytotoxic Safety — PPE Requirements

🚨Cytotoxic drugs are hazardous. Exposure causes carcinogenesis, mutagenesis, and teratogenesis. PPE is mandatory — never compromise.

Minimum PPE for Chemotherapy Handling

Gloves: Double nitrile chemotherapy-rated gloves (change every 30 min or if torn). No latex.
Gown: Long-sleeved, low-permeability, polyethylene-coated, closed front, cuffed. Single use.
Eye/Face protection: Chemical splash goggles AND face shield if aerosol/splash risk.
Respiratory: NIOSH-approved respirator (N95 minimum) during compounding.

Closed-System Transfer Devices (CSTDs)

Mechanically prevent escape of hazardous drug vapours/aerosols
Mandatory in many GCC institutions for cytotoxic preparation and administration
Examples: PhaSeal, ChemoClave, Equashield

Spill Management

Don PPE immediately (double gloves, gown, goggles)

Contain spill with absorbent material from spill kit (work inward from periphery)

Clean area 3 times with detergent then water

Dispose all materials as cytotoxic waste (yellow bag with cytotoxic symbol)

Document incident, report occupational exposure, seek occupational health review

Vesicant vs Irritant Classification

Vesicants — Cause Tissue Necrosis if Extravasated

Anthracyclines (doxorubicin, epirubicin) Vinca alkaloids (vincristine, vinblastine) Nitrogen mustards (mechlorethamine) Mitomycin C Taxanes (paclitaxel, docetaxel)

Irritants — Cause Inflammation but Not Necrosis

Cisplatin 5-Fluorouracil Carboplatin Ifosfamide Gemcitabine

Non-vesicants

Cyclophosphamide (oral/IV) Rituximab Bleomycin

⚠Know your drug's classification before administration. Check the institution's vesicant list annually — classifications can update.

Central Line Verification Before Chemotherapy

🚨NEVER administer vesicant chemotherapy without confirmed blood return. This is a critical safety checkpoint — no exceptions.

Pre-Administration Checks (5 Rights + Line Check)

Verify patient identity — 2 identifiers (name + MRN)

Confirm drug, dose, route, rate against prescription

Independent double-check by second qualified nurse (per protocol)

Assess line: flush with NS, confirm blood return, inspect for redness/swelling at site

Verify recent bloods: FBC, renal/hepatic function within protocol window

Confirm premedication administered (anti-emetics, steroids)

Extravasation Management Protocol

Anthracyclines (Doxorubicin, Epirubicin)

STOP infusion immediately; leave cannula in place briefly
Aspirate residual drug through cannula, then remove
Apply COLD compress (15–20 min, 4× daily for 72h)
Apply DMSO 99% topically q6h × 14 days (1–2 drops, dry — do not occlude)
Dexrazoxane IV (Savene): within 6h of extravasation on days 1, 2, 3
Mark extravasation area with permanent marker, photograph

Vinca Alkaloids (Vincristine, Vinblastine)

STOP infusion immediately; aspirate residual drug
Apply WARM compress (do NOT use cold — worsens necrosis)
Hyaluronidase SC injection into affected area (spreads enzyme, disperses drug)
Elevate limb, refer to plastic surgery if significant

Premedication Protocols

Standard Antiemetic Premedication

Drug	Class	Timing
Ondansetron 8 mg IV	5-HT₃ antagonist	30 min before chemo
Dexamethasone 8–20 mg IV	Corticosteroid	30 min before chemo
Fosaprepitant 150 mg IV	NK-1 antagonist	30 min before chemo (HEC)

HEC vs MEC Protocols

HEC (High Emetogenic — cisplatin, AC): Triple therapy: 5-HT₃ + dexamethasone + NK-1 antagonist ± olanzapine
MEC (Moderate — carboplatin, oxaliplatin): Dual therapy: 5-HT₃ + dexamethasone ± NK-1
Low emetogenic: Single agent (dexamethasone or prochlorperazine)

Hypersensitivity Premedication (Taxanes, Platinum)

Diphenhydramine 50 mg IV 30 min before
Dexamethasone 20 mg IV 30–60 min before (or night before + morning of)
Ranitidine 50 mg IV (or famotidine 20 mg IV)

Chemotherapy Calculations — Double-Check

BSA Calculation

Most chemo doses are based on Body Surface Area (BSA) in m².

Mosteller Formula: BSA = √[(Height(cm) × Weight(kg)) / 3600]

DuBois Formula: BSA = 0.007184 × H⁰·⁷²⁵ × W⁰·⁴²⁵

Double-Check Requirements

Two nurses independently calculate dose using current height/weight
Verify against prescription — report any discrepancy >5% before proceeding
Confirm dose capping if applicable (e.g., paclitaxel often capped at 2 m²)
Check dose reductions for renal/hepatic impairment or toxicity

Oral Chemotherapy Safety

⚠Oral cytotoxics (capecitabine, methotrexate, temozolomide) carry same hazards as IV. Handle with gloves. Never crush unless directed.

Educate patient on correct timing (with/without food — drug-specific)
Teach patient to avoid handling by carers who are pregnant
Emphasise adherence AND not doubling missed doses
Patient holds oral cytotoxics to pharmacy if no longer needed — do not dispose in household waste

Side Effect Management

CINV — Nausea & Vomiting (NCI CTCAE)

Grade	Nausea	Vomiting
1	Loss of appetite, no intake change	<1 episode/day above baseline
2	Decreased intake without weight loss/dehydration	2–5 episodes/day
3	Inadequate intake; IV fluids indicated <24h	≥6 episodes/day; IV fluids ≥24h needed
4	Life-threatening; urgent intervention required

Acute vs Delayed CINV

Acute: Within 24h post-chemo — managed with 5-HT₃ + dexamethasone ± NK-1
Delayed (Day 2–5): Aprepitant orally on days 2 and 3 (or netupitant/palonsetron as single-dose NEPA); dexamethasone days 2–4
Anticipatory: Conditioned response; treat with lorazepam, behavioural therapy

Oral Mucositis

Grade	Description	Intervention
1	Erythema, soreness	Soft diet, salt/bicarb rinses, lip balm
2	Patchy ulcers — can eat modified diet	Benzydamine mouthwash, analgesia, chlorhexidine rinse
3	Confluent ulcers — unable to eat solids	IV morphine PCA, IV nutrition, antifungal, antiviral if indicated
4	Tissue necrosis, life-threatening	ICU-level care; IV antibiotics; specialist referral

Prevention

Cryotherapy: Ice chips during bolus 5-FU infusions — reduces oral mucosal blood flow
Chlorhexidine 0.12% mouthwash — antiseptic, reduces secondary infection
Benzydamine mouthwash — NSAID-based, anti-inflammatory relief for Grade 1–2
Good oral hygiene before, during and after chemotherapy
Palifermin (KGF) for high-dose conditioning regimens (haematology)

Peripheral Neuropathy (CIPN)

Chemotherapy-Induced Peripheral Neuropathy — common with taxanes, platinum agents, vinca alkaloids, bortezomib.

Monitoring & Assessment

Assess at each cycle: tingling, numbness, pain in hands/feet
Use NCI CTCAE grading or FACT/GOG-NTX scale
Evaluate functional impact: buttoning clothes, fine motor, walking

Dose Reduction Criteria

Grade	Action
Grade 1	Continue — monitor closely each cycle
Grade 2	Consider dose delay/reduction 25%; document impact on ADLs
Grade 3	Hold drug; dose reduce or switch agent; gabapentin/duloxetine for pain
Grade 4	Discontinue causative agent; urgent neurology referral

Hand-Foot Syndrome (HFS)

Palmar-plantar erythrodysesthesia — common with capecitabine, 5-FU infusional, sorafenib.

Grade	Presentation	Management
1	Minimal skin changes — numbness, redness, tingling — no pain	Emollient creams (urea-based), avoid friction/heat, loose footwear
2	Skin changes with pain — affects function	25% dose reduction, topical steroids, pyridoxine (limited evidence)
3	Severe pain, severe skin changes — cannot perform ADLs	Hold treatment until ≤Grade 1; further dose reduction; wound care

Preventive Education

Begin emollients from day 1 of capecitabine (apply 2–3× daily)
Avoid tight shoes, hot water, friction activities
Report any blistering or cracked skin immediately

Cardiotoxicity Monitoring — Anthracyclines

Cumulative Dose Thresholds — Doxorubicin

Threshold	Action
Baseline (before treatment)	ECHO or MUGA scan — establish baseline LVEF
Cumulative dose ≥300 mg/m²	Repeat ECHO/MUGA — reassess LVEF
Cumulative dose ≥450 mg/m²	Mandatory ECHO/MUGA — risk-benefit discussion
>550 mg/m²	Significant cardiomyopathy risk — generally avoid unless benefit outweighs risk

Nursing Monitoring

Report new dyspnoea, peripheral oedema, or palpitations immediately
Track cumulative dose across all cycles — maintain running total in record
Ensure ECHO result reviewed before each cycle at threshold doses
Trastuzumab (Herceptin) also cardiotoxic — ECHO q3 months independently

⚠LVEF drop ≥10% from baseline OR LVEF <50% — hold anthracycline; urgent cardiology referral.

Alopecia & Fatigue

Chemotherapy-Induced Alopecia

Common with taxanes, anthracyclines, cyclophosphamide. Usually reversible — regrowth begins 3–6 months post-treatment.

Scalp cooling (cold cap): Reduces blood flow to hair follicles during infusion. Available in several GCC centres. Not suitable for haematological malignancies.
Prepare patient psychologically before treatment begins
Provide wig/head cover resources; discuss cultural sensitivity (hijab-wearing patients)
Reassure about reversibility — new hair may differ in texture/colour initially

Cancer-Related Fatigue (FACIT-F Scale)

Most prevalent unaddressed symptom in cancer. Multi-dimensional.

FACIT-Fatigue scale: 13 items, 0–52 — score ≤33 indicates significant fatigue
Assess anaemia (Hb threshold for ESA/transfusion per protocol)
Encourage structured exercise (proven to reduce fatigue)
Sleep hygiene, energy conservation strategies
Treat contributing factors: pain, depression, anaemia, hypothyroidism

Immunotherapy & Targeted Therapy

Checkpoint Inhibitors — Mechanism & Classes

PD-1 Inhibitors

Pembrolizumab (Keytruda) Nivolumab (Opdivo)

Block PD-1 receptor on T-cells, preventing tumour immune evasion.

PD-L1 Inhibitors

Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Avelumab (Bavencio)

Block PD-L1 on tumour cells, restoring T-cell activity.

CTLA-4 Inhibitors

Ipilimumab (Yervoy)

Block CTLA-4 checkpoint, enhancing early T-cell activation.

Often combined with PD-1 inhibitors — increases efficacy AND irAE risk.

Immune-Related Adverse Events (irAEs)

⚠irAEs can affect ANY organ. They mimic autoimmune conditions and may occur weeks to months after starting immunotherapy — even after treatment cessation.

Common irAE Patterns

System	Presentation	Key Assessment
Pneumonitis	New cough, dyspnoea, hypoxia	SpO₂, CXR/CT, RR
Colitis	Diarrhoea ≥4 stools/day, blood, cramps	Stool frequency, abdominal exam, colonoscopy
Hepatitis	Jaundice, RUQ pain, elevated LFTs	LFTs (AST/ALT), bilirubin
Endocrinopathies	Fatigue, hypo/hyperthyroid, adrenal crisis	TFTs, cortisol, fasting glucose
Skin	Rash, pruritus, vitiligo, SJS (rare)	Extent, blistering, mucosal involvement
Nephritis	Rising creatinine, haematuria, proteinuria	Urine dipstick, creatinine, urine PCR

irAE Grading & Management

Grade	Action
G1 — Mild	Continue immunotherapy; symptomatic management; monitor closely
G2 — Moderate	Hold immunotherapy; start oral prednisolone 1 mg/kg/day; specialist referral
G3 — Severe	Permanently hold; methylprednisolone IV 1–2 mg/kg/day; hospital admission; specialist consult
G4 — Life-threatening	Permanently discontinue; IV methylprednisolone 1–2 mg/kg/day; consider infliximab (colitis) or mycophenolate; ICU if needed

🚨Steroids are the mainstay — but do NOT use for endocrinopathies (manage with hormone replacement, not steroids alone).

Criteria for Permanent Discontinuation

Any Grade 4 irAE (excluding endocrinopathies managed with replacement)
Grade 3 myocarditis, pneumonitis, or neurotoxicity
Recurrent Grade 3 irAE despite dose hold and steroid taper
Grade 3–4 irAE not resolving to ≤Grade 1 within 12 weeks

Tyrosine Kinase Inhibitors (TKIs)

Drug	Target	Cancer	Key Monitoring
Imatinib (Gleevec)	BCR-ABL, c-KIT	CML, GIST	FBC (cytopenias), LFTs, oedema, weight
Erlotinib (Tarceva)	EGFR	NSCLC, pancreatic	Skin rash (marker of efficacy), diarrhoea, LFTs
Trastuzumab (Herceptin)	HER2	Breast, gastric	ECHO q3 months (LVEF), infusion reactions
Sorafenib (Nexavar)	Multi-kinase	Liver, renal, thyroid	BP monitoring, hand-foot syndrome, bleeding
Sunitinib (Sutent)	Multi-kinase	Renal, GIST	Hypertension, thyroid function, cardiac monitoring

ℹSkin rash with EGFR inhibitors (erlotinib, cetuximab) correlates with treatment response — manage proactively with moisturisers and topical antibiotics rather than dose-reducing early.

CAR-T Cell Therapy Awareness

Chimeric Antigen Receptor T-cell therapy — increasingly available in GCC tertiary centres.

Cytokine Release Syndrome (CRS)

Grade	Features	Management
G1	Fever ≥38°C	Supportive, paracetamol, IV fluids
G2	Fever + hypotension/hypoxia requiring low-flow O₂	Tocilizumab (IL-6 inhibitor) 8 mg/kg IV once
G3	Fever + hypotension (vasopressors) + high-flow O₂	Tocilizumab + corticosteroids; ICU transfer
G4	Life-threatening — mechanical ventilation/ECMO	ICU; tocilizumab; high-dose methylprednisolone; consider siltuximab

ICANS — Immune Effector Cell-Associated Neurotoxicity

Occurs concurrently or after CRS — confusion, tremor, aphasia, seizures
ICE (Immune Effector Cell Encephalopathy) score for grading: orientation, naming, command following, writing, attention
Grade ≥3: Dexamethasone, neurology involvement, seizure prophylaxis (levetiracetam)
Daily neurological assessment — report any new confusion or tremor immediately

⚠Tocilizumab does NOT cross the blood-brain barrier — it does not treat ICANS. Corticosteroids are the treatment for ICANS.

Palliative Oncology & Symptom Control

WHO Analgesic Ladder & Opioid Management

Three-Step Approach

Mild pain (NRS 1–3): Paracetamol 1g QDS ± NSAIDs (with PPI) ± adjuvants

Moderate pain (NRS 4–6): Add weak opioid — codeine 30–60 mg Q4H or tramadol 50–100 mg Q6H; continue Step 1

Severe pain (NRS 7–10): Strong opioid — morphine 5–10 mg oral Q4H (titrate); breakthrough dose = 1/6 of total daily dose PRN Q1H

Opioid Rotation — Equianalgesic Doses

Opioid	Oral (mg)	IV/SC (mg)
Morphine	30	10
Oxycodone	20	10
Hydromorphone	7.5	1.5
Fentanyl patch	25 mcg/h patch ≈ morphine 60–90 mg oral/24h
Methadone	Complex — specialist calculation only

⚠Reduce new opioid dose by 25–30% when rotating due to incomplete cross-tolerance. Always prescribe laxatives with opioids — opioid-induced constipation is almost universal.

Neuropathic Pain & Adjuvant Analgesics

Burning, shooting, electric, allodynia — consider neuropathic component in cancer pain.

Drug	Starting Dose	Titration	Notes
Gabapentin	100–300 mg nocte	Increase by 300 mg every 3–7 days; max 3600 mg/day in 3 divided doses	Dose-adjust for renal impairment; sedating — useful for sleep
Pregabalin	25–75 mg BD	Increase to 150–300 mg BD; max 600 mg/day	Linear pharmacokinetics — more predictable
Amitriptyline	10 mg nocte	Increase to 25–75 mg nocte	Caution in cardiac disease, urinary retention, elderly; anticholinergic
Duloxetine	30 mg OD	60 mg OD after 1 week	Also treats depression/anxiety; preferred for CIPN neuropathic pain
Dexamethasone	8–16 mg/day in AM	Taper to lowest effective dose	Excellent for nerve compression, bone pain, brain metastases

Malignant Bowel Obstruction (MBO)

Common in ovarian, colorectal, gastric cancers. Management depends on goals of care.

Conservative (Medical) Management

NBM + NG tube if vomiting severe — high-output decompression
Corticosteroids (dexamethasone 8–16 mg/day IV) — reduce peritumoral oedema
Antisecretory: Octreotide (SC/CSCI) 300–600 mcg/24h — reduces GI secretions
Antiemetic: Haloperidol or metoclopramide CSCI (not if complete obstruction)
Analgesia: Opioids via CSCI if unable to swallow
IV fluids for hydration — subcutaneous hydration at home possible

Surgical Considerations

Only appropriate if: good performance status, limited metastatic disease, single obstruction point, patient wishes intervention
Stenting (colonic stent) as palliative bridge in colorectal obstruction
Venting gastrostomy for symptom control (nausea/vomiting) without curative intent

Malignant Wounds

Fungating tumour wounds — breast most common; also head/neck, perineal. Cause significant distress.

Goals of Palliative Dressing

Odour control: Metronidazole gel 0.75–0.8% topically (anaerobe-targeted) or systemic metronidazole; activated charcoal dressings
Exudate management: Alginate or foam dressings for moderate exudate; super-absorbent for heavy exudate
Bleeding: Non-adherent dressings (e.g., Mepitel); alginate (haemostatic); adrenaline 1:1000 soaked gauze for acute bleeding; radiation if appropriate
Pain: Consider topical morphine (off-label) on wound surface; adequate systemic analgesia before dressing changes
Psychological: Maintain dignity; involve tissue viability and palliative care teams

ℹPalliative wound goals: symptom relief, odour control, patient dignity. Healing is rarely achievable — adapt dressing plan accordingly.

Last Days of Life — Anticipatory Medications

Prescribe anticipatory (Just In Case) medications in advance for the expected final 48–72 hours.

Syringe Driver Medications (Commonly Used)

Symptom	Drug	Typical 24h CSCI Dose
Pain	Diamorphine (SC)	Start: 1/3 previous oral morphine dose; titrate
Agitation / Restlessness	Midazolam	10–30 mg/24h (start low, titrate)
Nausea / Vomiting	Haloperidol	1.5–5 mg/24h
Respiratory secretions	Glycopyrronium	0.4–1.2 mg/24h (does not cross BBB)
Breathlessness	Midazolam ± low-dose opioid	Titrate to comfort

ℹReview syringe driver every 4h. Assess compatibility if mixing drugs. Document all changes and review rationale with family.

Goals of Care Conversations

Oncology nurses play a vital role in facilitating and supporting goals of care discussions.

Key Principles

Ask before telling: "What do you understand about where things are with your illness?" — SPIKES framework
Elicit patient priorities: What matters most to you? What are you most worried about?
Clarify misconceptions: About prognosis, treatment options, palliative care vs giving up
Cultural sensitivity: In GCC, family-centred decision-making is common — include family with patient consent
Document clearly: DNACPR status, preferred place of care, advance directives

SPIKES Framework

Setting: Private, unhurried environment; sit down

Perception: Assess patient's understanding of situation

Invitation: Ask how much information they want

Knowledge: Deliver information in plain language, in steps

Emotions: Respond to emotions with empathy; do not rush

Strategy/Summary: Clear plan; follow-up meeting arranged

GCC Oncology Context

Cancer Registries in the GCC

Country	Registry	Key Features
Saudi Arabia	Saudi Cancer Registry (SCR) — Ministry of Health	National population-based; largest in GCC
UAE	UAE National Cancer Registry	Federal; includes all seven emirates
Qatar	Qatar National Cancer Registry (QNCR)	Run by NCR, part of Hamad Medical Corporation
Kuwait	Kuwait Cancer Registry	Kuwait Cancer Control Centre
Bahrain	Bahrain Cancer Registry	Ministry of Health-operated
Oman	Oman Cancer Registry	Part of national health information system

ℹGCC data is improving but historically under-reported. Expatriate patients may not be fully captured. Nurses should ensure cancer diagnoses are registered per institutional protocol.

Leading Cancers in GCC

GCC cancer epidemiology differs from Western patterns due to demographics, diet, genetics, and lifestyle.

Higher Than Expected in GCC

Colorectal cancer — high red meat consumption, low fibre; younger age at presentation (40s–50s)
Breast cancer — leading cancer in women; often pre-menopausal at diagnosis
Thyroid cancer — high incidence, particularly papillary thyroid carcinoma
Haematological malignancies — lymphomas relatively prominent

Relatively Lower in GCC vs West

Lung cancer — lower due to lower historical smoking rates (though rising)
Prostate cancer — lower incidence, partly attributed to genetic/dietary factors
Cervical cancer — lower due to low HPV prevalence related to cultural practices

Late-Stage Presentation Challenges

Cultural & Social Factors Contributing to Late Presentation

Cancer stigma: Cancer associated with death and punishment in some communities — patients avoid seeking diagnosis
Symptom dismissal: Pain and fatigue attributed to overwork, ageing, or spiritual causes rather than medical evaluation
Fear of treatment: Chemotherapy perceived as causing death rather than treating disease
Privacy concerns: Fear of job loss, social isolation, or difficulty finding a spouse following diagnosis
Fatalism: "If God wills it" — sometimes misinterpreted as passive acceptance; may delay help-seeking
Expatriate workers: May avoid diagnosis fearing deportation or job loss; limited to employer-sponsored health access

Nursing Role in Addressing Late Presentation

Community cancer awareness campaigns — culturally adapted Arabic-language resources
Normalise screening (mammography, colonoscopy) in primary care
Non-judgmental communication; acknowledge beliefs while providing evidence-based information

Consanguinity & Hereditary Cancer in GCC

Consanguineous marriage (between first or second cousins) is more common in GCC countries — Saudi Arabia 50–60% of marriages, Kuwait ~54%, UAE ~40%.

Impact on Hereditary Cancer Syndromes

BRCA1/BRCA2 mutations: Studies show elevated founder mutations in Saudi and Gulf Arab populations. Young breast cancer (<45 years) should trigger referral for genetic testing.
Autosomal recessive conditions: Consanguinity increases risk of homozygous cancer predisposition syndromes (e.g., Fanconi anaemia, xeroderma pigmentosum)
Lynch Syndrome: Hereditary colorectal cancer — family history assessment critical in GCC populations given CRC burden

Nursing Actions

Three-generation family history on oncology admission
Flag for genetic counselling referral if family patterns noted
Educate families about genetic risk in culturally sensitive language

Ramadan Fasting During Chemotherapy

Managing cancer treatment during Ramadan requires sensitive, evidence-informed approach. Muslim patients have the right to choose; nurses should inform, not prescribe.

Clinical Concerns

Hydration: Extended fasting (12–18h) with cytotoxic drugs (especially cisplatin, methotrexate) that require forced hydration — significant dehydration risk
Oral medications: Timing of oral chemotherapy (capecitabine twice daily with food) disrupted
Drug metabolism: Altered circadian patterns may affect drug pharmacokinetics
Antiemetics: Patients may avoid prophylactic medications during fasting hours
Blood draws: Patient preference for fasting blood tests in early morning

Practical Nursing Guidance

Explore patient's intention regarding fasting — do not assume either way
Liaise with oncology team to schedule IV chemotherapy for after Iftar (breaking fast) where possible
Encourage pre-Suhoor (pre-dawn) hydration if fasting; encourage IV chemotherapy day hydration
Remind patients that Islamic scholars permit waiver of fasting during illness
Document Ramadan fasting status in care plan each year

Major Cancer Centres in GCC

Centre	Location	Notable Features
King Hussein Cancer Centre (KHCC)	Amman, Jordan (regional referral for GCC)	JCI-accredited; largest cancer centre in Arab world; training hub for GCC nurses
Cleveland Clinic Abu Dhabi (CCAD)	Abu Dhabi, UAE	Integrated oncology; bone marrow transplant programme
National Centre for Cancer Care & Research (NCCCR)	Doha, Qatar	Part of Hamad Medical Corporation; national cancer treatment centre for Qatar
King Faisal Specialist Hospital & Research Centre	Riyadh, Saudi Arabia	Haematology/BMT specialist; oldest tertiary cancer centre in KSA
Prince Sultan Military Medical City	Riyadh, Saudi Arabia	Military-affiliated oncology; expanding capability
Tawam Hospital	Al Ain, UAE	Oncology & haematology; Northern Emirates referral

Oncology Nursing Certification (OCN) in GCC

Oncology Certified Nurse (OCN) Credential

Awarded by the Oncology Nursing Certification Corporation (ONCC), USA — widely recognised in GCC.

Eligibility Requirements

Current RN licence in country of practice
Minimum 1 year experience as RN (12 months)
Minimum 1,000 hours oncology nursing practice within last 2.5 years
10 hours oncology nursing education within last 3 years

Exam Content Areas

Scientific basis for practice (disease/treatment)
Symptom management
Oncologic emergencies
Survivorship and palliation
Care continuum, ethics, legal principles

GCC Context for Certification

Many GCC hospitals incentivise OCN with salary increments and promotion criteria (e.g., Saudi, UAE JCI-accredited hospitals)
Saudi Oncology Society (SOS) and Emirates Oncology Society support local exam preparation workshops
CBON (Certified Bone Marrow Transplant Nurse) increasingly relevant given BMT expansion in KSA/UAE
Qatar NCCCR runs annual oncology nursing education days linked to ONS (Oncology Nursing Society) accreditation

Continuing Education Pathways

ONS (Oncology Nursing Society): Online modules, annual congress
ESMO Nursing: European Society for Medical Oncology nursing track
IPOS: Psychosocial oncology education
GCC local CPD: Annual oncology nursing conferences in UAE (Dubai) and Saudi Arabia

✓OCN certification correlates with improved patient outcomes, reduced medication errors, and higher nurse retention in oncology units.